GlassScriptPhysician profile
Katherine Mauldin
NPI 1407474695
$2,770.97
in general payments reported to CMS, 2019-2025
22 companies · $916 in 2025
The $916 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $398 · 2023: $131 · 2024: $1,174 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117 · Travel and Lodging: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.82 |
| Travel and Lodging | $104.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $636.24 | 2022-2025 | Eterna, Octrode |
| Globus Medical, INC. | $362.17 | 2025 | Senza, Vyrsa V1 |
| Abbvie INC. | $265.13 | 2021-2025 | |
| Pfizer INC. | $231.88 | 2024-2025 | |
| Mml US, INC. | $159.58 | 2024 | Reactiv8 |
| Teva Pharmaceuticals USA, INC. | $132.00 | 2024 | Uzedy |
| Nalu Medical, INC. | $130.01 | 2024 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $128.31 | 2023-2024 | Mild Device Kit |
| Bioventus LLC | $115.10 | 2022 | |
| Nevro Corp. | $107.36 | 2024 | Senza |
| Vertex Pharmaceuticals Incorporated | $92.32 | 2024-2025 | |
| Curonix LLC | $75.39 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $72.80 | 2024-2025 | Xtampza |
| Grt US Holding, INC. | $58.72 | 2022 | |
| Scilex Pharmaceuticals INC. | $49.82 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.44 | 2023 | Vpriv |
| Acacia Pharma INC | $23.61 | 2021 | |
| Pacira Therapeutics, INC. | $21.99 | 2021 | |
| Impel Pharmaceuticals INC. | $19.99 | 2022 | |
| Allergan, INC. | $14.77 | 2022 | |
| Almatica Pharma LLC | $13.64 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mauldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.